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SUMMARY Background
Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population.
Aim
To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems.
Methods
We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210À patients.
Results
The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210À patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 9 10 9 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210À patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210À patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368-94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968-44.180) were associated with poorer outcomes in the whole cohort.
INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic liver disease, characterised by the presence of anti-mitochondrial antibody (AMA) and destruction of interlobular bile ducts. In 2015, the nomenclature of PBC was changed from primary biliary cirrhosis to PBC. 1 There has been an extraordinary amount of work on both human and murine models of PBC that have addressed diagnosis, immunology and the genetic basis of disease. [2] [3] [4] [5] [6] [7] [8] [9] [10] However, the use of biomarkers to predict and understand prognosis has lagged behind. Anti-gp210 and anti-sp100 antibody are subgroups of anti-nuclear antibody (ANA) and their diagnostic values in AMA-PBC patients have been validated in many studies. 11, 12 Even though prior studies have suggested that anti-gp210 antibody was associated with a severe manifestation and a worse prognosis, [12] [13] [14] its role as a biomarker remains controversial. Five criteria including Paris-I, 15 Paris-II, 16 Rotterdam, 17 Barcelona 18 and Toronto 19 criteria have been widely applied to categorise responder and nonresponder patients after 1 or 2 years of ursodeoxycholic acid (UDCA) therapy. However, they still have limitations due to the complexity of PBC. 20 Recently, the GLOBE and UK-PBC scoring systems, which included parameters at baseline and after 1 year of UDCA therapy, have been designed and applied to predict long-term outcomes in PBC. 21, 22 However, these two scoring systems
have not yet been validated in Asian patients with PBC. We took advantage of the large number patients in our centre with relatively complete clinical data and comparatively higher anti-gp210 positive rate (around 50%) and conducted this retrospective study, attempting to validate of the UK-PBC and GLOBE scoring systems for prognosis of PBC in Chinese patients, to compare the clinical features and natural history between antigp210+ and anti-gp210À patients with PBC, and to see if ani-gp210 could affect the UK-PBC and GLOBE scoring systems.
METHODS
Patients
Patients with PBC who were referred to the Department of Gastroenterology and Hepatology of Shanghai RenJi Hospital from December 2004 to May 2016 were evaluated, the inclusion criteria were: (i) alkaline phosphatase (AKP) ≥1.5-fold of upper limit normal (ULN), positivity of AMA, PDC-E2, anti-gp210 or anti-sp100, or a liver biopsy specimen showing florid bile duct lesions;
(ii) anti-gp210 and anti-sp100 test were performed at presentation; (iii) UDCA therapy was initiated once the diagnosis was made and maintained at a dose of 13-15 mg/kg during follow-up; (iv) end-point data were available in May 2016. Exclusion criteria were: A positive serological test for hepatitis B or C virus, comorbidity of primary sclerosing cholangitis, alcoholic liver disease, hemochromatosis, Wilson's disease, a 1 -antitrypsin deficiency and presence of complications of cirrhosis (Total bilirubin >100 lmol/L, ascites, variceal haemorrhage and hepatic encephalopathy) on admission.
Study design
Baseline parameters (symptoms, biochemical, serological, radiological and histological features) were documented on initial presentation. Laboratory values were expressed as multiples of the ULN, while albumin and platelet levels were expressed as multiples of the lower limit of normal. Cirrhosis at presentation was assessed by computed tomography, magnetic resonance imaging or ultrasound examinations. Circulating autoantibodies including AMA, M 2 , antinuclear antibody (ANA), antismooth muscle antibody (ASMA), anti-gp210, antisp100, anti-liver kidney microsome antibody (LKM-1) and anti-soluble liver antigen/liver pancreas antigen (SLA/LP) were tested. Histological features including florid biliary damage, ductopaenia, lymphocyte aggregation, granulomas and cholestasis were evaluated, and the interface hepatitis was also assessed to exclude PBC-AIH overlap syndrome. The therapeutic regimens and treatment responses of the patients were all documented. All patients received UDCA therapy (13-15 mg/kg/day). In addition, fenofibrate (160-200 mg/day) was given to UDCA refractory patients. All patients were followed up at serial intervals of 1-3 months.
After 1 year of UDCA therapy, levels of AKP, gamma-glutamyltranspeptidase (GGT), total bilirubin (TB), alanine aminotransferase, aspartate aminotransferase, platelet and albumin were recorded, and shortterm responses were evaluated by the Paris-I, 15 Paris-II, 16 Rotterdam, 17 Barcelona 18 and Toronto 19 criteria, and two recently proposed scoring systems were also applied 21, 22 at a 1-year interval. The end-points of follow-up, as well as the definition of adverse outcomes were: The occurrence of PBC-related complications including ascites, variceal haemorrhage, hepatic encephalopathy, TB >100 lmol/L (on the basis of liver cirrhosis), orthotopic liver transplantation and liverrelated death. For those with more than one event, the data were recorded at the time when the first adverse outcome occurred. For patient followed up for more than 60 months, the end-point data were documented at May 2016.
Laboratory assessment
Serum protein electrophoresis and serum IgG concentration were assessed by immunonephelometry. ANA, ASMA and AMA were assessed via indirect immune fluorescence (IIF) on HEp-2 cells, monkey liver, rat kidney, and rat stomach tissue slides. M 2 , anti-gp210, anti-sp100, LKM-1 and SLA/LP were assessed by immunoblot assays (EUROASSAY test kit; EUROIMMUN, Luebeck, Germany). Hepatitis B serum markers (HBsAg, HBsAb, HBcAb, HBeAb and HBeAg) and antibodies to hepatitis C were assessed in all patients using second-generation ELISAs.
Histological analyses
Liver biopsies were assessed by two experienced pathologists (XY.C. and Q.M.) independently. Histological features of PBC recorded included florid bile duct lesions, ductopenia, granulomas and cholestasis; interface hepatitis was classified as none, mild (involving few foci in the biopsy), median (involving the majority of portal areas but extending around less than 50% of the circumference of most portal areas) and severe (involving more than 50% of the circumference of the majority of portal areas). 23 Fibrosis stage (0-4) and activity grade (0-3)
were assessed according to the METAVIR scoring system. 19 .0 (SPSS Inc., Chicago, IL, USA), all reported P value were two sided and a P < 0.05 was considered statistically significant.
Statistical analysis
RESULTS
Baseline and 1-year parameters in patients with or without adverse outcomes Baseline characteristics of the 276 patients with PBC, including 253 (92%) female and 23 (8%) male patients, were presented in Table 1 . The lost to follow-up were listed in Figure 1 . The median follow-up time was 36 months in the whole cohort [37 months for patients without adverse outcomes (n = 239) and 26 months for patients with adverse outcomes (n = 37)]. Of note, patients with poorer outcomes had statistically significant higher TB, aspartate aminotransferase, AKP, GGT levels, lower albumin levels and lower platelet counts. In addition, positive anti-gp210 and the presence of cirrhosis at presentation were also associated with unsatisfactory outcomes; 13 of the 17 (76.5%) AMA-negative PBC patients were positive for diagnostic specific ANAs. Of which, seven (41.2%) were anti-gp210+ and four (23.5%) were anti-sp100+, and another two (11.8%) were positive for both anti-gp210 and anti-sp100.
Test results including alanine aminotransferase, aspartate aminotransferase, AKP, GGT, TB, albumin and platelet were recorded in 229 patients after 1 year of UDCA therapy, and then five criteria and two scoring systems were applied to evaluate short-term responses. Notably, all these parameters analysed after 1 year of UDCA therapy were statistically significant different between patients with satisfactory and unsatisfactory outcomes (Table 1) .
In term of the treatment regimen, 79 patients received fenofibrate, including 44 (55.7%) anti-gp210+ patients and 35 (44.3%) anti-gp210-patients, while 197 patients received UDCA monotherapy, including 89 (45.2%) antigp210+ patients and 108 (54.8%) anti-gp210À patients (P = 0.143). Thirteen of the 79 patients (16.5%) who received combined therapy with UDCA and fenofibrate had adverse outcomes, while 24 of 197 patients (12.2%) who received UDCA monotherapy had adverse outcomes (P = 0.336).
Univariate analysis of baseline and 1-year parameters as prognostic indicators Among the baseline characteristics, the presence of cirrhosis at presentation (P < 0.001, HR: 13.68, 95% CI: 6.92-27.05), anti-gp210+ (P = 0.007, HR: 2.64, 95% CI: 1.31-5.35), TB ≥1.81 ULN (P < 0.001, HR: 13.43, 95% CI: 5.60-32.23), AKP ≥2.57 ULN (P = 0.004, HR: 3.40, 95% CI: 1.49-7.75), GGT ≥10.9 ULN (P = 0.003, HR: 2.80, 95% CI: 1.43-5.50), aspartate aminotransferase ≥2.26 ULN (P = 0.003, HR: 4.28, 95% CI: 1.67-11.00), platelet <153 9 10 9 (P < 0.001, HR: 5.72, 95% CI: 2.70-12.14) and albumin <40 g/L (P < 0.001, HR: 3.24, 95% CI: 1.69-6.18) were independent predictors of a poorer prognosis (Table 2 ). In terms of the parameters at 1 year, Paris-I criteria responder (P < 0.001, HR: 0.023, 95% CI: 0.003-0.166), Paris-II criteria responder (P = 0.001, HR: 0.032, 95% CI: 0.004-0.231), Rotterdam criteria responder (P < 0.001, HR: 0.035, 95% CI: 0.008-0.149) and Toronto criteria responder (P < 0.001, HR: 0.200, 95% CI: 0.098-0.410) predicted a better prognosis (Table 2) . ROC analysis revealed the optimal cut-off values for two new scoring systems. The optimal cut-off values for the UK scoring system and GLOBE scoring system were 0.0578 and 0.850 respectively. Patients with a UK Score >0.0578 demonstrated a worse prognosis (HR: 32.736, 95% CI: 11.368-94.267), and patients with a GLOBE Score <0.850 had a worse outcome (HR: 18.763, 95% CI: 7.968-44.180) ( Table 2) .
Short-term responses and 5-year adverse outcomefree survivals between anti-gp210+ and anti-gp210À patients with PBC We found anti-gp210+ and anti-gp210À patients with PBC had significant differences in long-term prognoses. The 5-year adverse outcome-free survivals of antigp210+ vs. anti-gp210À patients were 70% and 85%, respectively, (P = 0.005) (Figure 2 ), while the adverse outcome-free survivals in anti-sp100+ and anti-sp100À patients with PBC were almost the same (Figure 2 ). We divided patients into cirrhosis and noncirrhosis groups, and further dichotomise them into anti-gp210 positive and negative groups to ascertain the effect of cirrhosis on anti-gp210 responses. We note that antigp210+ PBC patients had significantly worse outcomes than anti-gp210-PBC patients only in the cirrhosis group (P = 0.001) (Figure 2 ). To better understand the differences between anti-gp210+ and anti-210À patients, we compared their baseline features. It turned out that anti-gp210+ patients with PBC had higher levels of TB (1.9 vs. 1.5 ULN, P < 0.001) and GGT (12.6 vs. 10.1 ULN, P = 0.002) (Table S1 ). No significant differences were found in other baseline characteristics. In addition, comparing the short-term responses between anti-gp210+ and anti-gp210À patients, we found that anti-gp210À patients had significantly higher response rate when evaluated by Paris-I, Paris-II and Rotterdam criteria, and also anti-gp210À patients had significantly lower UK-PBC score than anti-gp210+ patients (0.0482 vs. 0.0812, P = 0.003) after 1 year of UDCA therapy (Table S1 ).
The superimposition effects of other baseline risk factors on anti-gp210 antibody To further identify whether cholestatic parameters (TB, AKP and GGT) represented the only risk associated with anti-gp210, we further explored other clinical data in these patients (Table 2) . Using a Log-rank test, we found that anti-gp210+ patients with PBC presented statistically significant worse prognoses when combined with portal hypertension-associated risks besides cirrhosis: anti-gp210+ patients with albumin ≤40 g/L had worse prognoses than anti-gp210À patients with albumin ≤40 g/L (P = 0.011) ( Figure 3 ); anti-gp210+ PBC patients with platelet ≤153 9 10 9 had worse prognoses than anti-gp210À PBC patients with platelet ≤153 9 10 9 (P < 0.001) (Figure 3 ). However, anti-gp210+ patients were not statistically different from anti-gp210À patients when cholestatic risks such as TB ≥1.81 ULN (P = 0.078), AKP ≥2.57 ULN (P = 0.120) or GGT ≥10.9 ULN (P = 0.146) were added. For patients with albumin >40 g/L, with platelet >153 9 10 9 and with TB level <1.81 ULN, there were no statistically significant differences between anti-gp210+ and anti-gp210À groups. For patients with PBC with AKP <2.57 ULN and with GGT <10.9 ULN, anti-gp210À group had better prognosis than anti-gp210+ group, with P value being 0.002 and 0.043 respectively.
The effects of other baseline risk factors on cirrhosis
In addition to anti-gp210, we also analysed other risk factors (gender, TB, AKP, GGT and IgG) in the cirrhosis and noncirrhosis groups. In the noncirrhosis group ( Figure S1 A1-A4), patients with TB ≥1.96 ULN (P < 0.001), AKP ≥3.24 ULN (P = 0.003), GGT ≥22.7 ULN (P < 0.001) and IgG ≥1.22 ULN (P = 0.001) had a significantly worse prognosis. In the cirrhosis group ( Figure S1 B1-B4), patients with TB ≥1.57 ULN (P = 0.004) and GGT ≥6.8 ULN (P = 0.038) demonstrated a significantly worse prognosis. Gender did not affect the long-term prognosis in both the cirrhosis and noncirrhosis groups.
Application of UK-PBC and GLOBE scoring systems in whole cohort and subgroups divided by anti-gp210 antibody We did ROC analyses in the whole cohort and in antigp210 positive and negative subgroups (Figure 4) . The UK-PBC score and GLOBE score had relative higher predictive values in all three groups. For UK-PBC score, the area under ROC curve (AUROC) was 0.924 (95% CI: 0.877-0.971) for all patients with PBC (n = 223), 0.940 (95% CI: 0.890-0.990) for anti-gp210+ group (n = 110), and 0.888 (95% CI: 0.790-0.986) for antigp210À group (n = 113). As to GLOBE score, the area under ROC curve was 0.901(95% CI: 0.839-0.962) for all patients with PBC (n = 223), 0.924 (95% CI: 0.856-0.993) for anti-gp210+ subgroup (n = 110) and 0.848 (95% CI: 0.724-0.973) for anti-gp210À subgroup (n = 113) (Figure 4 ). Considering the anti-gp210+ group had larger area under ROC curve than anti-gp210À group when evaluated by either UK-PBC or GLOBE scoring system, and antigp210+ group had statistically significant higher GGT and TB levels than anti-gp210À group, we divided our patients by GGT and TB levels to see if these two parameters determined the higher prognostic values of UK-PBC and GLOBE scoring systems in anti-gp210+ patients with PBC. However, it turned out that patients with PBC with GGT >10.9 ULN had smaller area under ROC curve than patients with GGT ≤10.9 ULN by UK-PBC (0.876 vs. 0.948) and by GLOBE (0.845 vs. 0.947) scoring systems ( Figure S2 ). And patients with PBC with TB >1.81 ULN had smaller area under ROC curve than patients with TB ≤1.81 ULN by UK-PBC (0.806 vs. 0.967) or by GLOBE (0.817 vs. 0.933) scoring systems ( Figure S2) . Thus, the presence of higher GGT and TB level could not explain why the UK-PBC and GLOBE scoring systems were more suitable to anti-gp210+ patients with PBC.
Univariate and multivariate risk factor analysis of short-term response criteria and scoring systems in anti-gp210+ and anti-gp210À patients with PBC In the anti-gp210+ group, responders to Rotterdam criteria (P = 0.001, HR: 0.033, 95%CI: 0.004-0.248), Paris-I criteria (P = 0.007, HR: 0.013, 95% CI: 0.000-0.469), Paris-II criteria (P = 0.019, HR: 0.034, 95% CI: 0.001-0.737) and Toronto criteria (P = 0.001, HR: 0.218, 95% CI: 0.091-0.523) were associated with better long-term prognoses. And a UK-PBC score >0.0578 (P < 0.001, HR: 65.935, 95% CI: 8.788-494.698) and a GLOBE score <0.893 (P < 0.001, HR: 42.821, 95% CI: 5.728-320.143) indicated worse long-term outcomes. In multivariate analysis, UK-PBC score >0.0578 (P = 0.003, HR: 23.018, 95% CI: 2.814-188.300) and GLOBE score <0.893 (P = 0.033, HR: 9.767, 95% CI: 1.201-79.398) were found to have an independent predictive value (Table 3) .
In anti-gp210À group, responders to Rotterdam criteria (P = 0.003, HR: 0.044, 95% CI: 0.006-0.348), Paris-I criteria (P = 0.018, HR: 0.057, 95% CI: 0.007-0.452) and Toronto criteria (P = 0.009, HR: 0.191, 95% CI: 0.055-0.667) predicted better long-term prognoses; Meanwhile, UK-PBC score >0.0499 (P < 0.001, HR: 20.042, 95% CI: 4.216-95.265) and GLOBE score <0.829 (P < 0.001, HR: 16.000, 95% CI: 3.999-64.025) were associated with worse long-term outcomes. In multivariate analysis, GLOBE score <0.829 (P < 0.001, HR: 16.217, 95% CI: 3.975-66.166) and Toronto criteria (P = 0.024, HR: 0.208, 95% CI: 0.052-0.813) were found to have an independent predictive value ( Table 3) .
DISCUSSION
This study attempts to comprehensively explore the role of anti-gp210 as a prognostic indicator and to validate UK-PBC and GLOBE scoring system for the prognosis of PBC in Chinese population. In general, compared with the anti-gp210+ rate reported in previous studies in Japan (26.1%) 13, 15 and in Western countries (16%), 12, 13 the anti-gp210+ rate (48.2%) in our cohort was relatively higher. The differences in subgroups of ANA between PBC patients in our cohort and PBC patients from western countries 12, 13 may be attributed to the epigenetic differences. In addition, as our centre is a tertiary centre receiving patients from all over the country, the patients tend to be more heterogeneous and severe at presentation, which can be reflected from the baseline data (Table 1) . Since anti-gp210 is an indicator of more severe PBC that is associated with a worse prognosis, our patients with more severe manifestations at presentation may contribute to the relatively higher anti-gp210+ rate in our centre when compared with Nakamura's study (48.2% vs. 26.1%).
In the previous studies, anti-gp210 was regarded as an indicator of more pronounced cholestasis and more severely impaired liver function. 12, 13 Our study has confirmed the role of anti-gp210 in predicting poor prognosis and its association with cholestasis. In terms of the baseline features, anti-gp210+ group had higher TB value (1.9 vs. 1.5 ULN, P < 0.001) and GGT levels (12.6 vs. 10.1 ULN, P = 0.002).
In Kaplan-Meier survival plots, we found that portal hypertension-associated parameters, including the presence of cirrhosis, lower albumin levels and lower platelet count can contribute to a poor prognosis in anti-gp210+ group (Figures 2 and 3) . However, cholestatic parameters such as higher TB, AKP and GGT levels did not significantly contribute to a worse prognosis in anti-gp210+ group (Figure 3) . The above results, to some extent, implied that anti-gp210 positivity could be overlapped with cholestatic state, rather than portal hypertension state.
The UK-PBC and GLOBE scoring systems were proposed recently, the parameters included in UK-PBC scoring system were AKP, aspartate aminotransferase, TB, albumin and platelet, and the parameters concluded in GLOBE scoring systems were age, TB, AKP, albumin and platelet, none of them have taken into account of the anti-gp210, which could affect the prognostic value of the two scoring systems in our study. Furthermore, considering anti-gp210+ patients with PBC presented high GGT and TB levels at diagnosis, we stratified our patients by GGT (10.9 ULN) and TB (1.81 ULN), and then evaluated the subgroups by UK-PBC and GLOBE scoring systems. To our surprise, the UK-PBC and GLOBE scoring systems were more applicable to antigp210+ patients with PBC (Figure 4) , but, patients with lower GGT (GGT <10.9 ULN) or TB (TB <1.81 ULN) levels ( Figure S2 ). Thus, we proposed that anti-gp210 had its uniqueness, and could be added to further optimise the UK-PBC and GLOBE scoring systems.
In addition, what should be mentioned is that the end-point we chose was the presence of complications of cirrhosis (TB >100 lmol/L on the basis of cirrhosis, ascites, variceal haemorrhage, hepatic encephalopathy, liver transplantation and liver-related death), while in Carbone's and Willem's study, the end-point was defined as liver transplantation and liver-related death. Because we conducted a 5-year retrospective study, and there were only seven patients who suffered from liver transplantation or liver-related death during the follow-up, thus we did not choose them as the end-point. Although the end-point in our study was different from the prior studies, the UK-PBC and GLOBE scoring systems still hold a high prognostic value. In addition, we applied Toronto criteria after 1 year of UDCA therapy according to previous studies. 24, 25 One of the limitations of our retrospective study may be the incompleteness of the data, that is, not all parameters were completely available when we collected the data retrospectively although we did try our best. Objective symptom evaluations were not done in 52 (18.8%) patients, the baseline platelet count were not available in two (0.7%) patients, the immunoglobulin data (IgM and IgG) were not available in 21 (7.6%) patients, and the image evaluations were not performed in six patients (2.2%). We did not analyse short-term response in 47 (17.0%) patients because of missing data, in addition, the GLOBE score were not calculated in 53 (19.2%) patients because another six patients lack platelet data after 1 year of UDCA therapy (Figure 1) .
Another limitation of our study is the definition of cirrhosis. Although liver biopsy is considered the best way to evaluate fibrosis stage, many of our patients were diagnosed with cirrhosis by imaging studies. According to the guideline, the diagnosis of PBC could be established by the presence of AMA-or PBC-specific ANAs and elevated AKP level, thus, liver biopsy was not essential for the diagnosis of AMA-positive patients. Only patients who were AMA negative and those who were suspected to have PBC-AIH overlap syndrome were demanded to undertake liver biopsy. 26, 27 In addition, patients are reluctant to undertake liver biopsy because it is an invasive procedure. Thus, histological features were only available in 65 (23.6%) patients in our cohort. To ensure the completeness of our data, we adopted radiological methods to assess the presence of cirrhosis in patients without biopsy results. Meanwhile, when assessing the superimposed effects of risk factors (Figure 3) , we chose platelet count and albumin levels besides cirrhosis as portal hypertension-related markers to reduce the bias caused by subjective radiological evaluations. In multiple disciplines, including from autoimmunity to autism to end-stage liver failure, there is an increasing emphasis on defining biomarkers. [28] [29] [30] [31] We report herein that anti-gp210 was indeed associated with a more severe cholestatic manifestation at presentation and could also predict a worse prognosis (complications of cirrhosis, liver transplantation and liver-related death), especially when combined with another portal hypertension-related risk factors (the presence of cirrhosis, lower platelet count or lower albumin level) rather than another cholestatic risk factor (higher TB, AKP and GGT levels). In addition, we also validated the prognostic value of two newly proposed criteria (UK-PBC and GLOBE scoring systems) in the whole cohort and in subgroups divided by anti-gp210 antibody. We found that the UK-PBC and GLOBE scoring systems were good tools to evaluate short-term responses and long-term prognoses in Chinese patients with PBC, especially in anti-gp210+ patients, thus anti-gp210 antibody could be added to further optimise these two scoring systems.
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